Yvonne Mrtensson, CEO

1
CellaVision August 20 2009

• Yvonne Mårtensson, CEO

2

• CellaVision is world leaderin a market with
  large potential, offering Automated Digital Cell
  Morphology

3

• The hematology analysis market comprises more
  than 1 billion CBC tests a year manual
  differential work equivalent to more than
• USD 1 billion

4

• CellaVision market includes products to about
  15,000 laboratories worldwide
• The market value is estimated to minimum SEK 5
  billion
• In a mature market, products will be replaced in
  a 3-5 years cycle

5
Global Customer Base

• More than 500 systems mainly in Europe and North
  America
• Hospital and commercial hematology laboratories
• All customers have automatic blood cell counters
  for routine analysis
• Need for automation of manual cell differentials
• The operator is a biomedical scientist

6
CellaVisions Offering

• Analysis instruments
• CellaVision DM96
• CellaVision DM8
• CellaVision DM1200
• Optional Application for body fluids analysis
• CellaVision Body Fluid
• Software for remote access and networking
• CellaVision Remote Review Software
• Software for education/competency testing
• CellaVision Competency Software
• Accessories
• Service

7
Our Unique Technology Adds Value

• Efficiency cost reduction and increased
  productivity
• Proficiency increased quality of results
• Connectivity between sites enhanced opportunity
  for collaboration and sharing of competences.

8
Financial Performance 2001-2008 (MSEK)
9
Net sales by geographical marketUS direct sales
since 2008
2008 2007
10
Important achievements in 2008

• Net sales increased by 35 to SEK 100 million.
  Profit before income tax increased to SEK 13
  million
• Continued strong sales on the European market and
  an increase in North America.
• Establishment of own sales organization in the
  USA and subsidiary in Japan.
• Launch of application for body fluids in Europe
  and North America, with good initial sales
  results.

11
Significant events in 2009

• The new analyzer CellaVision DM1200 was
  presented in Europe and at the AACC in Chicago in
  July. The first orders were taken.
• CellaVision was awarded the SwedenBIO Award for
  its successes during 2008.
• CellaVisions Japanese subsidiary received its
  first order.
• CellaVision qualified for trade on the NASDAQ OMX
  First North Premier.

12
Interim report January 1 June 30, 2009

• Increased gross margin and next generation
  analyzer
• ready for launch
• Net sales for the period amounted to SEK 42.7
  million (41.3), an increase of 2
• The operating profit for the period was SEK 1.8
  million (2.8)
• The gross margin was 72 (62) during the period
  and 81 (61) during the second quarter

13
CellaVision Going Forward

• Hematology Business
• Continue sales growth
• Continue global market penetration
• Hardware cost reduction to extend market
• Refine business model to more recurrent revenue
• Software development, other applications like
  bone marrow
• Other Business Opportunities
• New market applications within cytology and
  histopathology based on CellaVision technology

14
Board
Lars Gatenbeck, Chairman Christer Fåhraeus
Niels P. Freiesleben Torbjörn Kronander
Sven-Åke Henningsson
15
Management Team
Yvonne Mårtensson, CEO Lars Juliusson, Sales
Dir. Hans-Inge Bengtsson, QA Manger Johan
Wennerholm, CFO Jeanette Bengtsson, Operations
MgrAdam Morell, RD Mgr Peter Wilson,
Marketing Mgr
16
For more information, please visit
www.cellavision.com
CellaVision was placed on NASDAQ OMX First North
Premieron the 16th of February.